DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fp8wr5/recurrent) has announced the addition of the "Recurrent Malignant Glioma - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Amgen Inc.
- AstraZeneca PLC
- Eisai Co., Ltd.
- Nerviano Medical Sciences S.r.l.
- Carboxyamidotriazole Orotate
- Carmustine SR
- Cell Therapy for Refractory Gliomas
- Cell Therapy to Target IL-13 for Malignant Glioma
- Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma
- Dendritic Cell Therapy for Oncology
- Sisufenton Sodium
For more information visit http://www.researchandmarkets.com/research/fp8wr5/recurrent